Date: 2015-01-19
Type of information: R&D agreement
Compound: Orexin-1 selective inhibitors
Company: Evotec (Germany) C4X Discovery (UK)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease: addictive disorders
Details: * On January 19, 2015, Evotec announced a research collaboration with C4X Discovery to optimise Orexin-1 selective inhibitors discovered through C4XD’s unique NMR technology. Evotec will apply its drug discovery platform with C4XD to further develop several series of Orexin-1 selective inhibitors. Activation of the orexin-1 receptor in the brain is associated with stress related addictive disorders (e.g. for alcohol, nicotine, cocaine and opiates), while the activation of the orexin-2 receptor is associated with biorhythms and wakefulness. Identification and development of selective compounds that inhibit the orexin-1 pathway thus should provide treatments for addiction avoiding the sedative effects associated with inhibition of orexin-2.
Financial terms: No financial details were disclosed.
Latest news:
